VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SNGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SNGXSoligenix, Inc.
$0.28$4M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
SNGX logo

Soligenix, Inc.

SNGX
NASDAQ · Immunology Biotech
$0.28
At close - Nov 17, 4:00 PM EST - USD
Market Cap$4M
P/E-0.7x
52W High$1.70
Volume257K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Outpaces Revenue Generation Potential

Soligenix remains a high-risk, pre-commercial biotechnology entity characterized by a total reliance on intermittent grant funding rather than sustainable product revenue.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

SNGX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-102% Peers

P/E is 102% below peer median

03

Market leadership

RS 17 · Lag

Laggard (Underperforming 83% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 6

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
SNGX-80.25%
S&P 500 (^GSPC)+7.21%
1-Year Return
SNGX-79.22%
S&P 500 (^GSPC)+10.03%
3-Year Return
SNGX-95.61%
S&P 500 (^GSPC)+61.77%
5-Year Return
SNGX-99.87%
S&P 500 (^GSPC)+55.88%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$11M-34.0% YoY
Free cash flow FY25
-$10M-22.2% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-
ROE (TTM)-165.9%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate1/12 (25%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 6, 2026
-$0.05+52.4%
vs -$0.10
—
vs —
Q3 2026
Aug 7, 2026
-$0.12+22.6%
vs -$0.15
—
vs —
Q2 2026
May 8, 2026
-$0.28+6.7%
vs -$0.30
—
vs —
Q2 2026
Apr 3, 2026
$0.32+218.5%
vs -$0.27
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
PRNewsWire·Nov 6, 2026
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended September 30, 2026.

Defense World·Aug 27, 2026
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's

Filtered for Soligenix, Inc.More Headlines
04

Compare before deciding

Benchmark SNGX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Soligenix, Inc. (SNGX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SNGX logoSNGXSoligenix, Inc.Current
$0.28$4.16M-0.70——-165.88%—
XTLB logoXTLBXTL Biopharmaceuticals Ltd.
$1.62$712.96K-0.10-100%———
ADXN logoADXNAddex Therapeutics Ltd
$3.50$2.52M-0.62-92.58%-14429.21%-172.46%—
NUVB logoNUVBNuvation Bio Inc.
$3.90$1.35B-10.10698.96%-67.38%-49.11%—
HALO logoHALOHalozyme Therapeutics, Inc.
$95.97$11.38B24.2437.55%26.93%544.26%—
AGEN logoAGENAgenus Inc.
$6.21$258.6M18.4110.37%20.98%——

Compare SNGX vs Peers

Soligenix, Inc. (SNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs XTLB

Most directly comparable listed peer for SNGX.

Scale Benchmark

vs IQV

Larger-name benchmark to compare SNGX against a more recognizable public peer.

Peer Set

Compare Top 5

vs XTLB, ADXN, NUVB, HALO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

SNGX SEC Filings & Documents

Soligenix, Inc. (SNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jun 26, 2026·SEC

Material company update

Jun 12, 2026·SEC

Material company update

May 28, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 21, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Aug 7, 2026·SEC

FY 2026

May 8, 2026·SEC

Get notified when SNGX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SNGX Frequently Asked Questions

Soligenix, Inc. (SNGX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is SNGX profitable?

No. Soligenix, Inc. (SNGX) reported a net loss of $8.8M over the trailing twelve months.

Dividend & Returns
What is SNGX's return on equity?

Soligenix, Inc. (SNGX) had a return on equity (ROE) of -165.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Soligenix, Inc.'s free cash flow?

Soligenix, Inc. (SNGX) had negative free cash flow of $8.2M over the trailing twelve months.

What if you invested $1,000 in SNGX back in 1995?

Total return calculator · dividends reinvested · 31+ years of data

See returns →